Advertisement

Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial

      Highlights

      • Novel trial design to evaluate cediranib and selumetinib independently with chemoradiotherapy in patients with locally advanced rectal cancer.
      • The combination with cediranib was well-tolerated and efficacious with 41% of patients achieving a pathological or clinical complete response.
      • The recommended phase 2 dose of cediranib is 20 mg/OD.
      • The maximum tolerated dose of selumetinib was not established because of toxicity.
      • Tumour necrosis factor alpha is a potential predictive biomarker, with significantly lower pre-treatment levels in patients that had an excellent response to treatment.

      Abstract

      Background

      The DREAMtherapy (Dual REctal Angiogenesis MEK inhibition radiotherapy) trial is a novel intertwined design whereby two tyrosine kinase inhibitors (cediranib and selumetinib) were independently evaluated with rectal chemoradiotherapy (CRT) in an efficient manner to limit the extended follow-up period often required for radiotherapy studies.

      Patients and methods

      Cediranib or selumetinib was commenced 10 days before and then continued with RT (45 Gy/25#/5 wks) and capecitabine (825 mg/m2 twice a day (BID)). When three patients in the cediranib 15-mg once daily (OD) cohort were in the surveillance period, recruitment to the selumetinib cohort commenced. This alternating schedule was followed throughout. Three cediranib (15, 20 and 30 mg OD) and two selumetinib cohorts (50 and 75 mg BID) were planned. Circulating and imaging biomarkers of inflammation/angiogenesis were evaluated.

      Results

      In case of cediranib, dose-limiting diarrhoea, fatigue and skin reactions were seen in the 30-mg OD cohort, and therefore, 20 mg OD was defined as the maximum tolerated dose. Forty-one percent patients achieved a clinical or pathological complete response (7/17), and 53% (9/17) had an excellent clinical or pathological response (ECPR). Significantly lower level of pre-treatment plasma tumour necrosis factor alpha (TNFα) was found in patients who had an ECPR. In case of selumetinib, the 50-mg BID cohort was poorly tolerated (fatigue and diarrhoea); a reduced dose cohort of 75-mg OD was opened which was also poorly tolerated, and further recruitment was abandoned. Of the 12 patients treated, two attained an ECPR (17%).

      Conclusions

      This novel intertwined trial design is an effective way to independently investigate multiple agents with radiotherapy. The combination of cediranib with CRT was well tolerated with encouraging efficacy. TNFα emerged as a potential predictive biomarker of response and warrants further evaluation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gerard J.P.
        • Conroy T.
        • Bonnetain F.
        • Bouche O.
        • Chapet O.
        • Closon-Dejardin M.T.
        • et al.
        Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
        J Clin Oncol. 2006; 24: 4620-4625
        • Bosset J.F.
        • Collette L.
        • Calais G.
        • Mineur L.
        • Maingon P.
        • Radosevic-Jelic L.
        • et al.
        Chemotherapy with preoperative radiotherapy in rectal cancer.
        N Engl J Med. 2006; 355: 1114-1123
        • Capirci C.
        • Valentini V.
        • Cionini L.
        • De Paoli A.
        • Rodel C.
        • Glynne-Jones R.
        • et al.
        Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.
        Int J Radiat Oncol Biol Phys. 2008; 72 (Epub 2008/04/15): 99-107
        • Rodel C.
        • Liersch T.
        • Becker H.
        • Fietkau R.
        • Hohenberger W.
        • Hothorn T.
        • et al.
        Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
        Lancet. 2012; 13: 679-687
        • Gerard J.P.
        • Azria D.
        • Gourgou-Bourgade S.
        • Martel-Laffay I.
        • Hennequin C.
        • Etienne P.L.
        • et al.
        Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
        J Clin Oncol. 2010; 28: 1638-1644
        • Navarro M.
        • Dotor E.
        • Rivera F.
        • Sanchez-Rovira P.
        • Vega-Villegas M.E.
        • Cervantes A.
        • et al.
        A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
        Int J Radiat Oncol Biol Phys. 2006; 66: 201-205
        • Gollins S.W.
        • Myint S.
        • Susnerwala S.
        • Haylock B.
        • Wise M.
        • Topham C.
        • et al.
        Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
        Br J Canc. 2009; 101: 924-934
        • Spigel D.R.
        • Bendell J.C.
        • McCleod M.
        • Shipley D.L.
        • Arrowsmith E.
        • Barnes E.K.
        • et al.
        Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.
        Clin Colorectal Cancer. 2012; 11 (Epub 2011/08/16): 45-52
        • Willett C.G.
        • Duda D.G.
        • di Tomaso E.
        • Boucher Y.
        • Ancukiewicz M.
        • Sahani D.V.
        • et al.
        Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
        J Clin Oncol. 2009; : 3020-3026
        • Jain R.K.
        Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
        Science. 2005; 307: 58-62
        • Batchelor T.T.
        • Gerstner E.R.
        • Emblem K.E.
        • Duda D.G.
        • Kalpathy-Cramer J.
        • Snuderl M.
        • et al.
        Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
        Proc Natl Acad Sci U S A. 2013; 110 (Epub 2013/11/06): 19059-19064
        • Williams K.J.
        • Telfer B.A.
        • Shannon A.M.
        • Babur M.
        • Stratford I.J.
        • Wedge S.R.
        Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.
        Mol Canc Therapeut. 2007; 6 (Epub 2007/02/20): 599-606
        • Resch G.
        • De Vries A.
        • Öfner D.
        • Eisterer W.
        • Rabl H.
        • Jagoditsch M.
        • et al.
        Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial.
        Radiother Oncol : J European Soc Ther Radiol Oncol. 2012; 102: 10-13
        • Crane C.H.
        • Eng C.
        • Feig B.W.
        • Das P.
        • Skibber J.M.
        • Chang G.J.
        • et al.
        Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
        Int J Radiat Oncol Biol Phys. 2010; 76 (Epub 2009/05/26): 824-830
        • Velenik V.
        • Ocvirk J.
        • Music M.
        • Bracko M.
        • Anderluh F.
        • Oblak I.
        • et al.
        Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
        Radiat Oncol. 2011; 6 (Epub 2011/09/02): 105
        • Wedge S.R.
        • Kendrew J.
        • Hennequin L.F.
        • Valentine P.J.
        • Barry S.T.
        • Brave S.R.
        • et al.
        AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
        Cancer Res. 2005; 65: 4389-4400
        • Yeh T.C.
        • Marsh V.
        • Bernat B.A.
        • Ballard J.
        • Colwell H.
        • Evans R.J.
        • et al.
        Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
        Clin Cancer Res : An Off J Am Assoc Cancer Res. 2007; 13 (Epub 2007/03/03): 1576-1583
        • Shannon A.M.
        • Telfer B.A.
        • Smith P.D.
        • Babur M.
        • Logie A.
        • Wilkinson R.W.
        • et al.
        The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.
        Clin Cancer Res. 2009; 15: 6619-6629
        • Mandard A.M.
        • Dalibard F.
        • Mandard J.C.
        • Marnay J.
        • Henry-Amar M.
        • Petiot J.F.
        • et al.
        Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. clinicopathologic Correlations.
        Cancer. 1994; 73 (Epub 1994/06/01): 2680-2686
        • Patel U.B.
        • Blomqvist L.K.
        • Taylor F.
        • George C.
        • Guthrie A.
        • Bees N.
        • et al.
        MRI after treatment of locally advanced rectal cancer: how to report tumor response--the MERCURY experience.
        AJR Am J Roentgenol. 2012; 199 (Epub 2012/09/22): W486-W495
        • Gollins S.
        • Sun Myint A.
        • Haylock B.
        • Wise M.
        • Saunders M.
        • Neupane R.
        • et al.
        Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
        J Clin Oncol : Off J Am Soc Clin Oncol. 2011; 29 (Epub 2011/01/26): 1042-1049
        • Backen A.C.
        • Cummings J.
        • Mitchell C.
        • Jayson G.
        • Ward T.H.
        • Dive C.
        Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use.
        J Immunol Methods. 2009; 342: 106-114
        • O'Connor J.P.
        • Jackson A.
        • Parker G.J.
        • Jayson G.C.
        DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.
        Br J Canc. 2007; 96 (Epub 2007/01/11): 189-195
        • Rosset A.
        • Spadola L.
        • Ratib O.
        OsiriX: an open-source software for navigating in multidimensional DICOM images.
        J Digit Imaging. 2004; 17: 205-216
        • Leach M.O.
        • Brindle K.M.
        • Evelhoch J.L.
        • Griffiths J.R.
        • Horsman M.R.
        • Jackson A.
        • et al.
        The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
        Br J Canc. 2005; 92: 1599-1610
        • Renehan A.G.
        • Malcomson L.
        • Emsley R.
        • Scott N.
        • O'Dwyer S.T.
        Watch-and-wait versus surgical resection for patients with rectal cancer - authors' reply.
        Lancet Oncol. 2016; 17 (Epub 2016/06/15): e134-e135
        • Rutella S.
        • Fiorino G.
        • Vetrano S.
        • Correale C.
        • Spinelli A.
        • Pagano N.
        • et al.
        Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease.
        Am J Gastroenterol. 2011; 106 (Epub 2011/03/03): 762-770
        • Janne P.A.
        • van den Heuvel M.M.
        • Barlesi F.
        • Cobo M.
        • Mazieres J.
        • Crino L.
        • et al.
        Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial.
        Jama. 2017; 317 (Epub 2017/05/12): 1844-1853
        • von Moos R.
        • Koeberle D.
        • Schacher S.
        • Hayoz S.
        • Winterhalder R.C.
        • Roth A.
        • et al.
        Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: a phase I/II trial (SAKK 41/08).
        Eur J Cancer. 2018; 89 (Epub 2017/12/15): 82-89